Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Capital Markets Day

On June 15th, Oasmia Pharmaceutical AB held a Capital Markets Day in Stockholm.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.

Research

At Oasmia, we’re developing the next generation of drugs with focus on oncology.

Production

At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share

News

Notification from Oasmia Pharmaceutical AB

Uppsala, Sweden, September 11, 2017 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, hereby issues a notification regarding t...
Read more

Oasmia Pharmaceutical AB (publ)

Interim report for the period May – July 2017
Read more

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) has, as has been previously announced, carried out a rights issue. The main part of the shares in the rights issue have b...
Read more
To news archive